USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA)AS… Application WO-2016144564-A2 World Intellectual Property Organisation (WIPO) 15 Sep 2016
Infection and treatment of neoplasms with vesicular stomatitis virus Grant US-8043612-B2 United States of America 25 Oct 2011
CLEARANCE OF NEOPLASTIC CELLS FROM MIXED CELLULAR COMPOSITIONS USING VIRUSES Grant EP-1278823-B1 European Patent Office 27 Jul 2011
Vaccinia virus host range genes to increase the titer of Avipoxviruses Application EP-2264178-A1 European Patent Office 22 Dec 2010
Use of vaccinia virus deleted for the E3L gene as a vaccine vector Application US-7431929-B2 United States of America 07 Oct 2008
Vaccinia virus MVA-E3L-knockout-mutants and use thereof Application US-7049145-B2 United States of America 23 May 2006
Viral vectors having reduced virulence Application US-6942855-B2 United States of America 13 Sep 2005
VACCINIA VIRUS HOST RANGE GENES TO INCREASE THE TITER OF AVIPOXVIRUSES Application WO-2004015118-A1 World Intellectual Property Organisation (WIPO) 19 Feb 2004
VACCINIA VIRUS MVA-E3L-KNOCKOUT-MUTANTS AND USE THEREOF Application WO-2003023040-A3 World Intellectual Property Organisation (WIPO) 27 Nov 2003
VACCINIA VIRUS MVA-E3L-KNOCKOUT-MUTANTS AND USE THEREOF Application WO-2003023040-A2 World Intellectual Property Organisation (WIPO) 20 Mar 2003
METHODS TO CONTROL THE HOST RANGE OF RETROVIRAL VECTORS Application WO-2002056668-A3 World Intellectual Property Organisation (WIPO) 13 Mar 2003
METHODS TO CONTROL THE HOST RANGE OF RETROVIRAL VECTORS Application WO-2002056668-A2 World Intellectual Property Organisation (WIPO) 25 Jul 2002